Stopping Sirolimus in KHE: A Careful Plan
Treatments studied
Part of Cancer, Skin clinical trials.
This study looks at different ways to stop taking sirolimus for children with KHE, a rare blood vessel tumor. It helps find the best plan to prevent the tumor from coming back after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child has been diagnosed with a rare blood vessel tumor called Kaposiform Hemangioendothelioma (KHE).
- You have been taking sirolimus and your doctor says it’s time to consider stopping it.
- You can be followed with regular check-ups, like blood tests or imaging scans, to watch for any signs of the disease coming back.
- You understand the study and can give permission (informed consent).
- Your blood counts, liver, and kidney function are good enough to safely take part in the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how the medicine sirolimus affects children’s response to routine vaccines during treatment for kaposiform hemangioendothelioma (KHE). It compares vaccinated KHE patients taking sirolimus with healthy children getting the same vaccines.
This study tests whether a low dose or a high dose of sirolimus (a drug that stops abnormal cell growth) combined with prednisolone (a steroid) works better for children with a rare, aggressive vascular tumor called KHE that also causes low blood platelets (KMP). The goal is to find the safest and most effective dose to help shrink the tumor and improve blood counts.
This trial tests different doses of sirolimus (a medication that slows cell growth) to find the best dose for treating cystic lymphatic malformations in children. It may help shrink the abnormal fluid-filled growths and improve symptoms.
This trial tests whether the drug sirolimus (rapamycin) can help people with dilated cardiomyopathy who also have a specific virus (KSHV) in their blood. It aims to see if sirolimus can improve heart function.
This trial tests a new form of sirolimus (a targeted therapy) for people with a rare cancer called EHE that is growing or causing symptoms. If you have EHE that can't be removed with surgery and needs treatment, this study may be an option.
This trial is studying a drug called nab-sirolimus for people with a rare type of vascular tumor called epithelioid hemangioendothelioma (EHE) that is growing or causing symptoms. The goal is to see if the drug can help control the tumor.
Hear when a new Kaposiform Hemangioendothelioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.